Axsome Therapeutics Inc (MEX:AZSM)
MXN 1519 0 (0%) Market Cap: 85.66 Bil Enterprise Value: 83.20 Bil PE Ratio: 0 PB Ratio: 42.15 GF Score: 39/100

Axsome Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 17, 2020 / 02:15PM GMT
Vikram Purohit;Herriot Tabuteau
Morgan Stanley, Research Division - Equity Analyst;Axsome Therapeutics, Inc. - Founder, Chairman, CEO & President

Great. Welcome, everyone. Let's go ahead and get started. So this is the fireside chat with Axsome Therapeutics. My name is Vikram Purohit. I'm one of the biotech analysts at Morgan Stanley.

Before we get into our Q&A, I need to read a brief disclosure statement. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

With that, let's kick it off. Happy to have with me Herriot Tabuteau, CEO of Axsome. Herriot, welcome.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot